CG Oncology Closes $47 Million Series D Financing | CG Oncology

CG Oncology Closes $47 Million Series D Financing | CG Oncology

4 weeks from now

IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced …

cgoncology.com

CG Oncology Closes $47 Million Series D Financing - BioSpace

4 weeks from now

Dec 10, 2020  · IRVINE, Calif.--(BUSINESS WIRE)-- CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, …

biospace.com

News Briefing: CG Oncology Nets $47M Series D For Bladder …

4 weeks from now

Dec 11, 2020  · CG Oncology has some new cash to play with. The Irvine, CA-based biotech announced Thursday it closed a $47 million Series D round of preferred stock financing as the …

labn.org

CG Oncology Closes $47 Million Series D Financing - 2020-12-10 ...

4 weeks from now

Dec 10, 2020  · CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 …

marketscreener.com

CG Oncology Closes $47 Million Series D Financing - Barchart.com

4 weeks from now

CG Oncology, Inc. , a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 million Series D …

barchart.com

BioBiz: Cancer Drug Developer, CG Oncology Snags $47M In Series …

4 weeks from now

Dec 11, 2020  · Irvine, CA-based CG Oncology, Inc, closed a $47 million Series D preferred stock financing led by new investor Kissei Pharmaceutical Co., Ltd., with participation from existing …

businessnewstribune.com

CG Oncology Closes $47M Series D Funding - Vcnewsdaily.com

4 weeks from now

CG Oncology, a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, announced the closing of a $47 million Series D preferred stock …

vcnewsdaily.com

CG Oncology Closes $47 Million Series D Financing

4 weeks from now

CG Oncology Closes $47 Million Series D Financing. 12/10/20. IRVINE, Calif.-- ... The financing will support the advancement of CG Oncology’s late-stage clinical programs for its lead …

citybuzz.co

CG Oncology Closes $47 Million Series D Financing - BioSpace

4 weeks from now

Dec 10, 2020  · CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced the closing of a $47 …

biospace.com

Cancer Therapeutics Firm Reels In $47M

4 weeks from now

Dec 20, 2020  · CG Oncology Inc. is ending 2020 on a high note, raising $47 million this month to support clinical trials of its cancer therapeutics. The financing round for the Irvine-based firm, …

ocbj.com

Oncolytic Immunotherapy Biotech CG Oncology Nabs $47M

4 weeks from now

Dec 11, 2020  · Californian immuno-oncology biotech CG Oncology has reeled in a $47 million series D—and, surely, an IPO isn’t far behind—as it looks to phase 3 trials. | Californian …

fiercebiotech.com

Series D - CG Oncology - 2020-12-10 - Crunchbase

4 weeks from now

Dec 10, 2020  · CG Oncology raised $47000000 on 2020-12-10 in Series D. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. Products. ... Business Wire — CG Oncology …

crunchbase.com

CG Oncology Closes $47 Million Series D Financing

4 weeks from now

IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, today announced …

cgoncology.com

CG Oncology Closes $47 Million Series D Financing

4 weeks from now

CG Oncology Closes $47 Million Series D Financing. by TechBear | Dec 10, 2020 | 2020. IRVINE, Calif., December 10, 2020 – CG Oncology, Inc., a clinical-stage biopharmaceutical company …

cgoncology.com

CG Oncology Closes $47 Million Series D Financing

4 weeks from now

On December 10, 2020 CG Oncology, Inc., a clinical-stage biopharmaceutical company focused on the development of novel oncolytic immunotherapies, reported the closing of a $47 million …

1stoncology.com

CG Oncology Announces $105 Million Oversubscribed Crossover …

4 weeks from now

Aug 2, 2023  · – Co-led by new investors Foresite Capital and TCGX – – Proceeds to advance late-stage clinical programs in bladder cancer towards FDA approval – August 2, 2023, 8:00 …

cgoncology.com

CG Oncology Raises $120 Million In Oversubscribed Series E …

4 weeks from now

IRVINE, Calif., November 15, 2022 – CG Oncology, Inc., an oncolytic immunotherapy company focused on developing novel therapeutics for patients with urologic cancers, today announced …

cgoncology.com

$22 Million Series C Financing - CG Oncology

4 weeks from now

– Investment to Advance Clinical Development of Oncolytic Immunotherapies in Bladder Cancer and other Solid Tumors – SANTA ANA, Calif., March 18, 2019 – Cold Genesys, Inc., a clinical …

cgoncology.com